Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Feb 14, 2012 12:35pm
264 Views
Post# 19531906

RE: Interesting ..Stoping in Nuggety and Flow Ore

RE: Interesting ..Stoping in Nuggety and Flow Ore

Terry:

[S] Looking at the job postings for core loggers, suggests that BRD is looking to reduce the response/reaction time from when a hole is drilled to when the adjustments in development and production (stoping) takes place.

Laying out stopes is extremely challenging in the nuggety ore. Thus flexibility of mining method selection must be paramout. The flow ore is more predictable. Alternatively I suspect that the Gibson, 147 and Contact must be under serious consideration for production source diversification especially if the regulatory hurdles are minimal.

BWDIK? Eventually some stocks bounce off the bottom... (e.g. NRI-v, the Pensaid for osteoarthritis solution).

GLAP-

Cheers

Stanley

 

 

Bullboard Posts